Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)
| العنوان: | Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1) |
|---|---|
| المؤلفون: | Fanyi Gan, Zhu Wu, Lunxu Liu, Weizhi Chen, Chengwu Liu, Yaohui Chen, Zheng Liu, Xiaolong Zhang, Yi-Dan Lin, Yong Yuan, Chuan Li, Gang Feng, Yunke Zhu, Lin Ma, Qiang Pu, Senyi Deng, Hu Liao, Chenglin Guo, Guowei Che, Ji He, Kaidi Li, Yun Wang, Ying-Li Kou, Feng Lin, Qingyun Li, Jiandong Mei, Wen-Ping Wang, Yuyang Xu, Ran Kang, Yulan Deng, Yang Hu, Liang Xia, Long-Qi Chen, Yang Ying |
| المصدر: | Clinical Cancer Research. 28:3308-3317 |
| بيانات النشر: | American Association for Cancer Research (AACR), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, education.field_of_study, Lung cancer surgery, business.industry, Population, Perioperative, medicine.disease, Internal medicine, medicine, Adjuvant therapy, Biomarker (medicine), Stage (cooking), business, Lung cancer, education, Cohort study |
| الوصف: | Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a biomarker for early detection of molecular residual disease (MRD) and prediction of postoperative relapse in resected non–small cell lung cancer (NSCLC). Experimental Design: Based on our prospective, multicenter cohort on dynamic monitoring of ctDNA in lung cancer surgery patients (LUNGCA), we enrolled 950 plasma samples obtained at three perioperative time points (before surgery, 3 days and 1 month after surgery) of 330 stage I–III NSCLC patients (LUNGCA-1), as a part of the LUNGCA cohort. Using a customized 769-gene panel, somatic mutations in tumor tissues and plasma samples were identified with next-generation sequencing and utilized for ctDNA-based MRD analysis. Results: Preoperative ctDNA positivity was associated with lower recurrence-free survival (RFS; HR = 4.2; P < 0.001). The presence of MRD (ctDNA positivity at postoperative 3 days and/or 1 month) was a strong predictor for disease relapse (HR = 11.1; P < 0.001). ctDNA-based MRD had a higher relative contribution to RFS prediction than all clinicopathologic variables such as the TNM stage. Furthermore, MRD-positive patients who received adjuvant therapies had improved RFS over those not receiving adjuvant therapy (HR = 0.3; P = 0.008), whereas MRD-negative patients receiving adjuvant therapies had lower RFS than their counterparts without adjuvant therapy (HR = 3.1; P < 0.001). After adjusting for clinicopathologic variables, whether receiving adjuvant therapies remained an independent factor for RFS in the MRD-positive population (P = 0.002) but not in the MRD-negative population (P = 0.283). Conclusions: Perioperative ctDNA analysis is effective in early detection of MRD and relapse risk stratification of NSCLC, and hence could benefit NSCLC patient management. |
| تدمد: | 1557-3265 1078-0432 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::314f7d3b2485c714ced80384dd231eef https://doi.org/10.1158/1078-0432.ccr-21-3044 |
| رقم الأكسشن: | edsair.doi...........314f7d3b2485c714ced80384dd231eef |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15573265 10780432 |
|---|